脂联素是由脂肪组织特异性分泌的具有胰岛素增敏作用的激素，在血清内以低聚体、中聚体和高聚体的形式存在，其中高聚体是脂联素调控代谢作用的主要活性形式。通过提高脂联素高聚体在血清中所占的比例，可以有效地改善2型糖尿病患者的胰岛素敏感性，同时也为开发和研制治疗2型糖尿病的药物开辟了新的研究领域。 我们的前期研究证明，激活AMPK信号通路能够促进脂联素高聚体的形成。LPL(Lipoprotein Lipase)是脂蛋白代谢中重要的脂蛋白酯肪酶，主要催化乳糜微粒和极低密度脂蛋白中甘油三酯的分解。本实验室前期实验发现，LPL可以与脂联素多聚体结合，并且促进脂联素的高聚化。在本项目中，我们将进一步验证LPL与脂联素之间的相互结合，探究LPL调控脂联素高聚化的分子机制。本课题将揭示LPL的新功能，为深入研究脂联素高聚化的调控机制，寻找机体内治疗2型糖尿病新型药物靶点奠定理论基础。

Adiponectin is an important insulin-sensitizing adipokine with multiple beneficial effects on obesity-associated medical complications. It is secreted from adipocytes into the circulation as trimer (LMW), hexamer (MMW) and the high-molecular-weight (HMW) of 18-36 monomers, with the HMW oligomer possessing the most potent insulin-sensitizing activity. The composition of adiponectin oligomers in circulation, particularly the ratio of HMW to total adiponectin, varies under different obesity-related pathological conditions, and can be reversed by pharmacological and lifestyle interventions. Therefore, adiponectin is a promising candidate for the development of drugs to treat type 2 diabetes and other related metabolic diseases. LPL (lipoprotein lipase) is an enzyme that hydrolyzes triglycerides in lipoproteins, such as chylomicrons and very low-density lipoproteins. LPL was identified as one of the proteins which can be immunoprecipitated by antibodies specific for adiponectin oligomers in our research. We found that LPL interacts with adiponectin and promotes adiponectin multimerization. In this study, we will investigate the molecular mechanism by with LPL promotes adiponectin multimerization. This study reveals a novel function of LPL, which will help to identify potential drug targets for the treatment of type 2 diabetes.